Apellis Pharmaceuticals Inc Sustainability Reports

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds for autoimmune and rare diseases through complement system inhibition.

Sector: Manufacturing

Country: United States

Exchange: Nasdaq

LEI: 254900HS0ZFRXXSB9D42

FIGI: BBG007KGRPZ3

6 reports from 2018 to 2024

• Apellis Pharmaceuticals Inc 2024 Annual Report
• Apellis Pharmaceuticals Inc 2023 Form 10-K
• Apellis Pharmaceuticals Inc 2021 Form 10-K
• Apellis Pharmaceuticals Inc 2021 Sustainability Report
• Apellis Pharmaceuticals Inc 2020 Form 10-K